Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 19/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886316 | 0.98 | OPRK1 (0.66) | OPRK1OPRM1 | |
| SCHEMBL11931972 | 0.94 | OPRK1 (0.69) | OPRK1OPRM1 | |
| SCHEMBL20363363 | 0.92 | OPRK1 (0.65) | OPRK1OPRM1CTSK | |
| SCHEMBL20363368 | 0.92 | OPRK1 (0.63) | OPRK1OPRM1CTSK | |
| SCHEMBL17132155 | 0.92 | OPRK1 (0.73) | OPRK1OPRM1 | |
| SCHEMBL21286538 | 0.90 | OPRK1 (0.60) | OPRK1OPRM1 | |
| SCHEMBL19249464 | 0.90 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL21233466 | 0.89 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL24360679 | 0.88 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL24360678 | 0.88 | OPRK1 (0.62) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885CTSK 1542/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885OPRM1 3/4885CTSK 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.